Zobrazeno 1 - 7
of 7
pro vyhledávání: ''
Autor:
Asher Ornoy, Gideon Koren
Publikováno v:
Expert Review of Clinical Pharmacology. 11:373-385
It was assumed for decades that the human placenta serves as a barrier, protecting the fetus from exposure to xenobiotics circulating in the mother. The thalidomide disaster completely reversed this concept. The study of the human placenta is therefo
Publikováno v:
Expert Review of Clinical Pharmacology. 11:219-231
The tyrosine kinase inhibitor (TKI) imatinib was rationally designed to target BCR-ABL1 which is constitutively activated in chronic myeloid leukemia (CML). Following the tremendous success in adults, imatinib also became licensed for treatment of CM
Autor:
Ron Milo, Michael Osherov
Publikováno v:
Expert Review of Clinical Pharmacology. 10:1037-1047
The goal of the article is to review the mechanism of action and the use of daclizumab, a humanized monoclonal antibody (mAb) against the alpha subunit of the high affinity interleukin-2 (IL-2) receptor, in the treatment of Multiple Sclerosis (MS). A
Publikováno v:
Expert Review of Clinical Pharmacology. 10:783-788
The pharmacokinetic (PK) profile of tenofovir disoproxil fumarate in Chinese adults infected with HIV is unknown.A pilot, prospective, open-label study was performed to investigate the steady-state PK profile of tenofovir disoproxil fumarate in 15 Ch
Publikováno v:
Expert Review of Clinical Pharmacology. 10:699-705
Olaratumab is a humanized IgG1 monoclonal antibody that blocks the platelet-derived growth factor receptor alpha (PDGFRα). Its antagonistic behavior inhibits the receptor's tyrosine kinase activity, thereby, turning off the downstream signaling casc
Publikováno v:
Expert Review of Clinical Pharmacology. 9:1493-1503
WHO recommends tenofovir, efavirenz, and lamivudine or emtricitabine for first-line antiretroviral therapy (ART) in adults, which replaced more toxic regimens using stavudine, zidovudine or nevirapine. Areas covered: We searched Pubmed to identify ob
Autor:
R. Donald Harvey, Jesús F. San-Miguel, Philippe Moreau, Paul G. Richardson, Jacob P. Laubach, Sagar Lonial
Publikováno v:
Expert Review of Clinical Pharmacology. 9:35-48
Recently, outcomes for patients with multiple myeloma have improved dramatically due to improved and innovative therapies. However, most patients will either relapse or become refractory to current therapy. Thus, a significant unmet need remains for